Major Depressive Disorder Clinical Trial
Official title:
Treatment for Chronic Depression With Behavioral Interventions
The purpose of this study is to test the clinical efficacy of two psychotherapies for early onset chronic major depression, including Behavioral Activation (Jacobson et al., 2001), and an integrated version of Behavioral Activation and Stress Innoculation Coping (BASIC) for short-term (16 weeks) of individual psychotherapy for adults with chronic major depression. The control condition is an individual workbook condition of Behavioral Activation. These psychotherapies focus on behavior activation, stress reduction and coping strategies to counter depressive symptoms.
Early-onset unipolar major depression is linked with considerable morbidity and mortality
(Birmaher et al., 1996). The goal of this project is to test the efficacy of Behavioral
Activation (BA; Jacobson et al., 2001) and an integrated version of Behavioral Activation
(BA + Stress Inoculation Coping; BASIC) for the short-term psychotherapy of adults with
chronic major depression (onset before age 18) and a history of early life stress before age
18. Exposure to stress during the developmental years has been linked with early-onset
depression (Rao et al., 1996), a propensity to generate stress during the life span (Hammen
et al., 1998), and a greater psychological sensitivity to stress as an adult (Post et al.,
1992). And while incidence of early life stress is high among depressed adults, there are no
behavioral treatments designed to address the unique needs of these individuals. We aim to
develop a new treatment for a specific group of depressed patients, namely individuals who
report early onset of depression and early life stress. We include the critical elements of
behavioral activation and stress reduction strategies to address the avoidance, stress
sensitivities, and coping deficits often observed in this population.
The specific aims are: 1) to determine if the addition of stress reduction strategies
(packaged in BASIC) enhance the effects of BA, as indexed by the rate early remission; 2) to
investigate if exposure to BA and BASIC reduce risk of relapse within three months of
treatment termination, as indexed by reduced rates of relapse by the 3-month follow-up; and,
3) to learn if effects of BA are mediated by changes in activity behaviors or the
acquisition of compensatory behavioral skills, and likewise whether enduring effects of
BASIC are mediated by changes in stress regulation or the acquisition of stress regulation
skills. Our approach is to compare BA and BASIC to a self-guided bibliotherapy of BA
(control condition) using a randomized clinical trial design to distinguish between
conditions. We anticipate that this study will promote our understanding about the efficacy
of BA and the discovery of mechanisms of treatment response. We expect this project to
facilitate our understanding of the mechanisms that promote treatment gains and contribute
to depressive relapse.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05537558 -
Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)
|
||
Terminated |
NCT02192099 -
Open Label Extension for GLYX13-C-202, NCT01684163
|
Phase 2 | |
Completed |
NCT03142919 -
Lipopolysaccharide (LPS) Challenge in Depression
|
Phase 2 | |
Recruiting |
NCT05547035 -
Identification of Physiological Data by a Wearable Monitor in Subjects Suffering From Major Depression Disorders
|
N/A | |
Terminated |
NCT02940769 -
Neurobiological Effects of Light on MDD
|
N/A | |
Recruiting |
NCT05892744 -
Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression
|
Phase 4 | |
Recruiting |
NCT05537584 -
SMART Trial to Predict Anhedonia Response to Antidepressant Treatment
|
Phase 4 | |
Active, not recruiting |
NCT05061706 -
Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
|
Phase 3 | |
Completed |
NCT04479852 -
A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder
|
Phase 2 | |
Recruiting |
NCT04032301 -
Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans
|
Phase 1 | |
Recruiting |
NCT05527951 -
Enhanced Measurement-Based Care Effectiveness for Depression (EMBED) Study
|
N/A | |
Completed |
NCT03511599 -
Cycloserine rTMS Plasticity Augmentation in Depression
|
Phase 1 | |
Recruiting |
NCT04392947 -
Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation
|
N/A | |
Recruiting |
NCT05895747 -
5-HTP and Creatine for Depression R33 Phase
|
Phase 2 | |
Recruiting |
NCT05273996 -
Predictors of Cognitive Outcomes in Geriatric Depression
|
Phase 4 | |
Recruiting |
NCT05813093 -
Interleaved TMS-fMRI in Ultra-treatment Resistant Depression
|
N/A | |
Recruiting |
NCT05135897 -
The Neurobiological Fundaments of Depression and Its Relief Through Neurostimulation Treatments
|
||
Enrolling by invitation |
NCT04509102 -
Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder
|
Early Phase 1 | |
Recruiting |
NCT06026917 -
Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET)
|
Phase 4 | |
Recruiting |
NCT06145594 -
EMA-Guided Maintenance TMS for Depression
|
N/A |